SymBio Pharmaceuticals Limited (4582.T)
JPY 173.0
(0.58%)
JPY 173.0
(0.58%)
| Year | Operating Income | Operating Income Growth |
|---|---|---|
| 2023 | -811.66 Million JPY | -141.34% |
| 2022 | 1.96 Billion JPY | 93.27% |
| 2021 | 1.01 Billion JPY | 122.55% |
| 2020 | -4.5 Billion JPY | -4.76% |
| 2019 | -4.3 Billion JPY | -61.95% |
| 2018 | -2.65 Billion JPY | 32.71% |
| 2017 | -3.94 Billion JPY | -85.57% |
| 2016 | -2.12 Billion JPY | 16.64% |
| 2015 | -2.55 Billion JPY | -95.79% |
| 2014 | -1.3 Billion JPY | 22.45% |
| 2013 | -1.68 Billion JPY | 1.16% |
| 2012 | -1.7 Billion JPY | 17.74% |
| 2011 | -2.06 Billion JPY | -237.28% |
| 2010 | -612.79 Million JPY | -194.57% |
| 2009 | -208.02 Million JPY | -256.58% |
| 2008 | 132.85 Million JPY | 0.0% |
| Year | Operating Income | Operating Income Growth |
|---|---|---|
| 2024 Q1 | -806.7 Million JPY | -52.65% |
| 2024 Q3 | -1.07 Billion JPY | -17.39% |
| 2024 Q2 | -912.78 Million JPY | -13.15% |
| 2023 Q4 | -528.46 Million JPY | -126.35% |
| 2023 Q1 | 51.24 Million JPY | -86.33% |
| 2023 FY | -811.66 Million JPY | -141.34% |
| 2023 Q2 | -100.97 Million JPY | -297.04% |
| 2023 Q3 | -233.47 Million JPY | -131.21% |
| 2022 Q4 | 374.76 Million JPY | 918.09% |
| 2022 FY | 1.96 Billion JPY | 93.27% |
| 2022 Q1 | 509.2 Million JPY | -13.95% |
| 2022 Q2 | 863.27 Million JPY | 69.53% |
| 2022 Q3 | 36.81 Million JPY | -95.74% |
| 2021 Q3 | 619.17 Million JPY | 3874.96% |
| 2021 Q1 | -210.51 Million JPY | 84.56% |
| 2021 FY | 1.01 Billion JPY | 122.55% |
| 2021 Q4 | 591.76 Million JPY | -4.43% |
| 2021 Q2 | 15.57 Million JPY | 107.4% |
| 2020 FY | -4.5 Billion JPY | -4.76% |
| 2020 Q2 | -878.03 Million JPY | 8.72% |
| 2020 Q1 | -961.91 Million JPY | -25.7% |
| 2020 Q3 | -1.3 Billion JPY | -48.34% |
| 2020 Q4 | -1.36 Billion JPY | -4.71% |
| 2019 Q3 | -1.52 Billion JPY | -7.19% |
| 2019 Q2 | -1.41 Billion JPY | -138.13% |
| 2019 FY | -4.3 Billion JPY | -61.95% |
| 2019 Q4 | -765.26 Million JPY | 49.7% |
| 2019 Q1 | -595.94 Million JPY | 20.39% |
| 2018 Q4 | -748.56 Million JPY | -28.43% |
| 2018 FY | -2.65 Billion JPY | 32.71% |
| 2018 Q1 | -714.52 Million JPY | -62.8% |
| 2018 Q2 | -610.11 Million JPY | 14.61% |
| 2018 Q3 | -582.86 Million JPY | 4.47% |
| 2017 Q3 | -2.27 Billion JPY | -219.74% |
| 2017 FY | -3.94 Billion JPY | -85.57% |
| 2017 Q1 | -525.2 Million JPY | 11.69% |
| 2017 Q2 | -710.67 Million JPY | -35.31% |
| 2017 Q4 | -438.88 Million JPY | 80.69% |
| 2016 FY | -2.12 Billion JPY | 16.64% |
| 2016 Q4 | -594.73 Million JPY | 16.51% |
| 2016 Q1 | -518.4 Million JPY | 66.85% |
| 2016 Q2 | -301.53 Million JPY | 41.83% |
| 2016 Q3 | -712.37 Million JPY | -136.25% |
| 2015 Q1 | -332.29 Million JPY | 1.29% |
| 2015 Q3 | -339.72 Million JPY | -7.62% |
| 2015 FY | -2.55 Billion JPY | -95.79% |
| 2015 Q4 | -1.56 Billion JPY | -360.36% |
| 2015 Q2 | -315.67 Million JPY | 5.0% |
| 2014 Q3 | -320.39 Million JPY | -38.87% |
| 2014 FY | -1.3 Billion JPY | 22.45% |
| 2014 Q4 | -336.62 Million JPY | -5.07% |
| 2014 Q2 | -230.71 Million JPY | 44.48% |
| 2014 Q1 | -415.54 Million JPY | 14.77% |
| 2013 Q2 | -466.13 Million JPY | -36.69% |
| 2013 Q3 | -385.79 Million JPY | 17.24% |
| 2013 Q4 | -487.57 Million JPY | -26.38% |
| 2013 FY | -1.68 Billion JPY | 1.16% |
| 2013 Q1 | -341.02 Million JPY | 26.12% |
| 2012 Q3 | -364.38 Million JPY | 7.44% |
| 2012 Q4 | -461.56 Million JPY | -26.67% |
| 2012 FY | -1.7 Billion JPY | 17.74% |
| 2012 Q1 | -480.64 Million JPY | -55.51% |
| 2012 Q2 | -393.67 Million JPY | 18.09% |
| 2011 Q1 | -410.82 Million JPY | 0.0% |
| 2011 Q2 | -290.5 Million JPY | 29.29% |
| 2011 Q3 | -1.05 Billion JPY | -263.65% |
| 2011 Q4 | -309.08 Million JPY | 70.74% |
| 2011 FY | -2.06 Billion JPY | -237.28% |
| 2010 Q4 | - JPY | 0.0% |
| 2010 Q2 | - JPY | 0.0% |
| 2010 FY | -612.79 Million JPY | -194.57% |
| 2009 Q4 | - JPY | 0.0% |
| 2009 FY | -208.02 Million JPY | -256.58% |
| 2008 FY | 132.85 Million JPY | 0.0% |
| Name | Operating Income | Operating Income Difference |
|---|---|---|
| Pharma Foods International Co., Ltd. | 5.11 Billion JPY | 115.875% |
| Takeda Pharmaceutical Company Limited | 214.07 Billion JPY | 100.379% |
| Sumitomo Pharma Co., Ltd. | -354.19 Billion JPY | 99.771% |
| Shionogi & Co., Ltd. | 171.46 Billion JPY | 100.473% |
| Wakamoto Pharmaceutical Co.,Ltd. | -195.51 Million JPY | -315.152% |
| Nippon Shinyaku Co., Ltd. | 31.38 Billion JPY | 102.586% |
| Kaken Pharmaceutical Co., Ltd. | 9.51 Billion JPY | 108.532% |
| Eisai Co., Ltd. | 53.4 Billion JPY | 101.52% |
| Morishita Jintan Co., Ltd. | 716 Million JPY | 213.361% |
| Hisamitsu Pharmaceutical Co., Inc. | 13.16 Billion JPY | 106.164% |
| Mochida Pharmaceutical Co., Ltd. | 5.8 Billion JPY | 113.987% |
| Fuso Pharmaceutical Industries,Ltd. | 1.96 Billion JPY | 141.327% |
| Nippon Chemiphar Co., Ltd. | -494 Million JPY | -64.305% |
| Tsumura & Co. | 20.01 Billion JPY | 104.055% |
| Kissei Pharmaceutical Co., Ltd. | 4.01 Billion JPY | 120.206% |
| Torii Pharmaceutical Co., Ltd. | 5.03 Billion JPY | 116.117% |
| Towa Pharmaceutical Co., Ltd. | 17.64 Billion JPY | 104.599% |
| Fuji Pharma Co., Ltd. | 3.85 Billion JPY | 121.039% |
| Zeria Pharmaceutical Co., Ltd. | 9.71 Billion JPY | 108.353% |
| KYORIN Holdings, Inc. | 6.01 Billion JPY | 113.499% |
| Taiko Pharmaceutical Co.,Ltd. | -3.07 Billion JPY | 73.639% |
| Daito Pharmaceutical Co.,Ltd. | 3.89 Billion JPY | 120.844% |
| MedRx Co., Ltd | -933 Million JPY | 13.005% |
| Mizuho Medy Co.,Ltd. | 5.15 Billion JPY | 115.754% |
| Solasia Pharma K.K. | -1.13 Billion JPY | 28.739% |
| Modalis Therapeutics Corporation | -2.37 Billion JPY | 65.752% |
| ASKA Pharmaceutical Holdings Co.,Ltd. | 6.5 Billion JPY | 112.487% |
| Sawai Group Holdings Co., Ltd. | 18.88 Billion JPY | 104.298% |
| Cyfuse Biomedical K.K. | -697.43 Million JPY | -16.379% |
| Toho Holdings Co., Ltd. | 19.33 Billion JPY | 104.199% |
| Koa Shoji Holdings Co.,Ltd. | 4.38 Billion JPY | 118.521% |